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An epidemic of severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2) originating in 
Wuhan, China has, within a short period of time, 
spread around the world. World Health Organiza-
tion declared coronavirus disease 2019 (COVID-19) 
a pandemic. As of April 3rd, 2020 there are 1074,017 
confirmed cases with 58,004 deaths. Like SARS-
CoV and Middle Eastern respiratory syndrome 
(MERS)-CoV, SARS-CoV-2 is a coronavirus that can 
be transmitted to humans. These viruses are all re-
lated to high mortality in critically ill patients [1, 2]. 
The clinical spectrum of SARS-CoV-2 pneumonia 
ranges from mild to critically ill cases. The most 
common symptoms at the onset of COVID-19 illness 
are fever, cough, and fatigue, while other symptoms 
include sputum production, headache, hemoptysis, 
diarrhea, dyspnea, and lymphopenia [3–5].
Mechanical ventilation is the main supportive 
treatment for critically ill patients. In the case of 
SARS, the key element of the procedure is addi-
tionally low-pressure ventilation strategies with 
low tidal volume (Vt) ventilation (Vt 4–8 mL/kg of 
predicted body weight) and targeting plateau pres-
sures (Pplat) of < 30 cm H2O and higher positive 
end-expiratory pressure strategy. This reduces 
ventilator-induced lung injury [6]. In order to save 
the lungs and in the era of a limited number of 
available (unoccupied) ventilators, extracorporeal 
oxygenation membrane (ECMO) may be help-
ful in treating patients with COVID-19. ECMO 
is a resource-intensive technique restricted to 
specialized centers, and it remains an extremely 
limited resource. Though there are no clinical 
trials of ECMO in COVID-19 patients. However 
a recent report from China suggested that 11.5% of 
COVID-19 cases in the intensive care unit received 
ECMO [7] (however, the results on these patients 
have not yet been published). 
Extracorporeal oxygenation membrane is one 
of the methods of extracorporeal circulation and 
ventilation support. For the first time good results 
of ECMO treatment of acute respiratory failure 
were published in 1979 in the United States after 
15 years of research on its effectiveness. The main 
objective of ECMO is to oxygenate the blood and 
eliminate carbon dioxide outside the patient’s body. 
The ECMO system consists of cannulas connecting 
the extracorporeal circulation with the patient’s 
vascular system, centrifugal pump, oxygenator and 
drainage system. 
Extracorporeal oxygenation membrane thera-
py can be divided into two methods: venous-venous 
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or venous-arterial. In the case of venous-venous 
ECMO, blood is collected and donated to the ve-
nous system. Most often in the right femoral vein, 
it is used as a drain of the venous system and the 
right internal jugular vein is used as the return 
line to the patient. This variant allows only for 
respiratory support, which is exactly what is used 
in patients with COVID-19 who have developed 
severe respiratory failure. In patients requiring 
circulatory support, blood is taken from the venous 
system and returned to the arteries, thus relieving 
the heart (venous-arterial ECMO).
Combes et al. [8] in EOLIA trial stated that 
the analysis of the primary end point (mortality 
at 60 days) in their trial involving patients with 
very severe acute respiratory distress syndrome 
showed no significant benefit of early ECMO, 
as compared with a strategy of conventional me-
chanical ventilation, which included crossover to 
ECMO, but when used as a rescue modality ECMO 
might help improve survival (28% crossover pa-
tients) [8]. In turn, Pham et al. [9] have shown 
that patients who received ECMO therapy during 
the influenza A (H1N1) pandemic in 2009 appeared 
to benefit.
Extracorporeal Life Support Organization 
(ELSO, Ann Arbor, MI, USA, www.elso.org) is 
a worldwide non-profit patronage organization of 
more than 450 centers with units providing almost 
130,000 ECMO per year. The main mission of 
ELSO is to collect registry of ECMO treatments 
and provide guidelines associated with extracorpor-
eal treatment. Among the indications of ECMO ve-
nous-venous therapy lists, among others, extreme 
respiratory failure not responding to conventional 
treatment, acute respiratory distress syndrome 
(including influenza), respiratory disorders in the 
course of sepsis or asthma. However, contraindi-
cations for the use of ECMO therapy should be 
taken into account, including: contraindications for 
chronic heparinization, irreversible lesions causing 
cardiovascular or respiratory failure, or as a rela-
tive contraindication — hemorrhagic flaw and/or 
presence of potential bleeding [10]. 
Since the beginning of the year, ELSO [11] has 
been actively uniting specialists from around the 
world to adapt the inclusion and exclusion criteria 
to extracorporeal therapies during a pandemic. 
It must remembered, that in certain healthcare 
systems, caregivers are challenged to deal with 
a growing number of patients with a significant 
reduction in equipment and personnel resources. 
In such therapies, ECMO therapy may often seem 
impossible. Therefore, in addition to clinical cri-
teria, many centers providing ECMO therapies 
have to face the introduction of new criteria that 
take into account limited resources, including age 
criteria or patient co-morbidities.
Extracorporeal oxygenation membrane re-
mains an option for the treatment of patients with 
severe respiratory failure in patients in selected 
age groups with minor co-morbidities. It is very 
labor-intensive procedure, but may be a life-saving 
treatment. ECMO will not replace mechanical 
ventilation or equipment shortages of ventilator 
availability. ECMO requires supervision by very 
experienced and well-trained specialist medical 
personnel, but nevertheless remains a therapeutic 
option in some well selected patients.
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